UFP TECHNOLOGIES (UFPT)·Q4 2025 Earnings Summary

UFP Technologies Beats EPS Again, but Revenue Softens as Q4 Growth Slows to 3%

February 24, 2026 · by Fintool AI Agent

UFP Technologies (NASDAQ: UFPT) reported Q4 2025 results that continued its streak of EPS beats but showed a marked deceleration in revenue growth. The medical device contract manufacturer delivered adjusted EPS of $2.44, beating consensus by 12%, while revenue of $148.9 million came in slightly below the $149.6 million estimate . The quarter caps a record year with 19.5% revenue growth and 15.8% net income expansion, though Q4's 3.4% top-line growth signals the acquisition-fueled momentum is normalizing .

Did UFP Technologies Beat Earnings?

UFP Technologies extended its EPS beat streak to 9 consecutive quarters . The pattern is consistent: management delivers on profitability while revenue occasionally comes up short. Q4's organic sales were essentially flat year-over-year, with the 3.4% reported growth driven entirely by M&A contributions .

Full Year 2025 Results:

What Drove the Results?

Medical segment (+4.2% YoY) remained the growth engine, reaching $138.2 million or 93% of Q4 revenue . Full-year medical sales jumped 23.2% to $555.3 million, driven by acquisitions and new program launches.

Non-medical segment (-6.0% YoY) contracted to $10.7 million as the company continues pivoting away from lower-margin industrial markets .

Gross margin pressure persisted at 28.2%, down from 29.2% in Q4 2024, though the gap narrowed from earlier quarters . The AJR labor issue absorbed $1.2 million in Q4, a significant improvement from $3.0 million in Q3 .

What Did Management Say About the AJR Labor Issue?

The AJR facility in Illinois has been a persistent headwind throughout 2025. CEO R. Jeffrey Bailly addressed the improving trajectory:

"We achieved the 14.1% earnings growth despite absorbing approximately $6.3 million in labor-related inefficiencies at our AJR facility. Of note, the impact in Q4 dropped to $1.2 million, less than half of the $3.0 million impact in Q3. We expect to make continued progress until the issue is resolved."

The labor disruption stemmed from workforce eligibility verification issues that caused significant attrition. Management's language suggests they see a path to resolution in 2026.

What Changed From Last Quarter?

The sequential revenue decline reflects typical seasonality, but the improving labor situation and gross margin recovery are encouraging signs heading into 2026.

How Did the Stock React?

UFPT shares traded down 2.3% in after-hours following the release, with aftermarket trades at $235 versus the $240.57 regular-session close. The stock had rallied strongly heading into earnings, gaining 5.5% on February 20 and another 3.5% on February 23 .

Year-to-date, UFPT shares are up approximately 9% from the ~$220 level at the start of 2026, though still below the 52-week high of $275.51.

What Did Management Guide For 2026?

Management did not provide specific financial guidance but struck a bullish tone on multiple fronts:

Dominican Republic Expansion:

"In La Romana, we extended our contract with our largest customer through 2029, increasing volumes on current programs and adding a new program. We also launched three new programs, and after taking possession of a fifth building in 2025, we will soon add a sixth facility to accommodate anticipated growth."

Safe Patient Handling Market:

"In Santiago, we successfully launched our second transfer program and plan to add a new facility in Q2 2026, which will allow us to localize and ramp up a third major program in the Safe Patient Handling space. This market opportunity is substantial, with significant growth anticipated again in 2026."

M&A Integration:

"The four acquisitions we completed in 2024 and three we completed in 2025 are all progressing well with integrations either well underway or complete. With new talent in place across the Company, new programs recently launched, new contract extensions with several major customers, and a robust pipeline, we remain bullish about our future."

Wall Street Forward Estimates

*Values retrieved from S&P Global

Analysts are modeling mid-single-digit revenue growth for 2026, with EPS growth accelerating as AJR labor costs normalize and integration synergies flow through.

Key Risks and Concerns

1. Customer concentration — The company's two largest customers account for a substantial portion of revenue, with supply agreements subject to volume variability

2. Tariff exposure — Management flagged risks from "governmental regulations and/or sanctions affecting the import and export of products, including global trade barriers, additional taxes, tariff increases"

3. Dominican Republic execution — Multiple facility expansions and program transfers carry integration and ramp-up risk

4. Organic growth remains muted — FY 2025 organic growth was just 1.5%, with Q4 essentially flat, raising questions about underlying demand trends

Balance Sheet Highlights

UFP Technologies meaningfully deleveraged in 2025, reducing total debt by $54 million while growing equity by $81 million. The strong free cash flow generation positions the company for additional M&A or accelerated debt paydown.

The Bottom Line

UFP Technologies delivered another quarter of EPS outperformance, extending its beat streak to nine quarters. However, the slowdown in organic growth and continued margin pressure from AJR labor issues tempered the results. The bullish commentary on Dominican Republic expansion, customer contract extensions, and the resolving AJR situation sets up a potentially stronger 2026 — but execution on multiple fronts needs to materialize.

The after-hours weakness suggests investors wanted more than operational commentary; specific 2026 guidance would have been welcomed given the growth deceleration.

Conference Call: Wednesday, February 25, 2026 at 8:30 AM ET

---

View UFPT Company Profile · Q3 2025 Earnings · Latest Transcript